Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
28 hedge funds and large institutions have $11.5M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 11 closing their positions.
95% more call options, than puts
Call options by funds: $127K | Put options by funds: $65K
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
18% less capital invested
Capital invested by funds: $14.1M → $11.5M (-$2.57M)
26% less funds holding
Funds holding: 38 → 28 (-10)
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.08M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$273K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$192K |
| 4 |
Renaissance Technologies
New York
|
+$160K |
| 5 |
BlackRock
New York
|
+$98.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.09M |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
-$438K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
-$296K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$159K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$141K |
FRTX Hedge Fund Activity: Q2 2018 in Review
28 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q2 2018, worth a combined $11.5M — down 18% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of FRTX and 1 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Armistice Capital, adding an estimated $3.08M. The largest seller was Eventide Asset Management, cutting an estimated $2.09M.
- 28 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q2 2018, down from 38 in Q1 2018.
- Funds reported $11.5M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q2 2018, down 18% quarter-over-quarter.
- 1 fund opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q2 2018 and 11 closed out, a net change of -10 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q2 2018 was Armistice Capital, an estimated $3.08M added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q2 2018 was Eventide Asset Management, an estimated $2.09M sold.
Based on aggregated 13F filings for Q2 2018.